Elligo Health Research, a healthcare-enabling research organization, is working with Verily to support the Project Baseline COVID-19 Program. The program is a collaboration with the California Governor’s office, federal, state and local public health authorities, to expand COVID-19 risk screening and testing. Three initial sample-collection sites were launched Monday, March 16 in San Mateo County and Santa Clara County. Additional locations are expected in the coming weeks.
“COVID-19 is presenting unprecedented challenges for our customers, partners and communities. In this extraordinary situation it is imperative that those of us in healthcare and clinical research work together to advance new and innovative ways to mitigate the risks of COVID-19,” said Chad Moore, Elligo President. “Whatever we can do to serve communities in need, we will.”
Elligo’s mission has always been to bring clinical research directly to clinical healthcare, solving patient access challenges by enabling research as a care option. Their existing capabilities enabled Elligo to immediately contribute to these important efforts. As the response to the COVID-19 pandemic evolves, Elligo remains committed to expanding access to healthcare to those in need and helping to better understand the epidemiology of the virus.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.